Parameter
| Biomarker | MGMT | Full name | O⁶-methylguanine-DNA methyltransferase | Molecular Type | Protein / Nucleic acid (DNA methylation) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognosis, Prediction |
| Disease | Cervical Cancer | Disease Subtypes | / | ||
| Organ | Cervix | Test Sample / Technology Platform | Tumor tissues (IHC, methylation-specific PCR, NGS) | ||
| Pathobiological Mechanisms | Repairing DNA damage induced by alkylating agents, promoter methylation leads to expression silencing and loss of repair function. | ||||
| Clinical Availability Status | In research validation / clinical translation: Gradually applied to individualized selection of chemotherapy regimens | ||||
| Notes and Dynamics | The MGMT promoter methylation in patients leads to a 30% increase in the response rate to chemotherapy with drugs like temozolomide, and a 6-8 month extension of the median survival period. | ||||